GHRH Peptide Eliminates Calcium Buildup in Blood Vessels of Diabetic Mice | Research

The takeaway

A growth hormone-releasing hormone peptide analog reversed vascular calcification and eliminated heart valve calcium plaques in diabetic mice without raising growth hormone levels.

Calcium plaques disappeared
Heart valve calcium deposits visible on echocardiography were eliminated after 8 weeks of GHRH agonist treatment in diabetic mice

What the researchers found

A growth hormone-releasing hormone agonist (MR409) reversed vascular calcification in diabetic mice over 8 weeks of daily treatment. The peptide eliminated calcium plaques from heart valves (confirmed by echocardiography), improved blood vessel function, and reduced vascular structural damage — all without significantly affecting growth hormone levels.

The mechanism involved upregulation of the anti-calcifying protein Klotho, reduction of vascular reactive oxygen species (ROS), and suppression of bone-forming genes (Runx2, ALP) that drive calcium deposition in blood vessels. The peptide also improved the lipid profile of diabetic mice.

Why it matters

Vascular calcification — calcium buildup in blood vessel walls and heart valves — is a major killer in diabetes and has no approved treatment. Current medicine can't reverse it once it starts. This study shows a peptide analog of GHRH can not only prevent but appear to reverse established calcification in diabetic mice, without triggering the problematic growth hormone elevation that limits other GHRH-based therapies. If this translates to humans, it could address a massive unmet medical need.

The numbers in context

8-week daily treatment · calcium plaques eliminated from heart valves · ALP and Runx2 expression reduced · Klotho upregulated · ROS reduced · lipid profile improved · no significant GH axis effect

How the study worked

Animal study using db/db diabetic mice (a standard genetic model of type 2 diabetes). Mice received daily subcutaneous injections of MR409 (a GHRH agonist) for 8 weeks. Researchers assessed vascular calcification using echocardiography and calcium staining, measured osteogenic markers (ALP, Runx2), anti-calcifying protein Klotho, reactive oxygen species, lipid profiles, and endothelium-dependent vascular relaxation.

Who was studied

Diabetic db/db mice (genetic model of type 2 diabetes with obesity)

What this study cannot tell us

Mouse model only — db/db mice develop severe diabetes that may not fully represent the gradual vascular calcification seen in human diabetics over decades. The 8-week treatment period is short relative to the chronic nature of human vascular disease. No dose-response data mentioned. The apparent disappearance of heart valve calcium plaques on echo needs histological confirmation. Long-term safety and effects on other organs were not assessed.

How to read the evidence

Preliminary evidence from a single animal study. While the results are striking — apparent reversal of calcification with a clear mechanistic pathway — this is a mouse model only. Vascular calcification in humans develops over decades and may respond differently. No human data exists for this application.

When this study was published

Published in 2023. This is recent preclinical work. GHRH agonists for vascular calcification are a novel research direction with no clinical trials yet reported for this specific application.

The bigger picture

Vascular calcification affects millions of people with diabetes, kidney disease, and aging. The fact that no approved treatment exists makes this a critical unmet need. GHRH agonists are an unexpected candidate for this role — they're being explored primarily for cancer and growth hormone deficiency. This study's finding that MR409 works through Klotho (an anti-aging protein that declines with age and diabetes) rather than through growth hormone opens up a novel therapeutic mechanism that could have applications beyond diabetes.

Questions still open

Can MR409 reverse established vascular calcification in humans with type 2 diabetes?
Why does a GHRH agonist upregulate Klotho without significantly activating the growth hormone axis?
Would this peptide also benefit vascular calcification in non-diabetic conditions like chronic kidney disease or aging?

Common questions

What is vascular calcification and why can't we treat it?

Vascular calcification is the buildup of calcium in blood vessel walls and heart valves, making them hard and stiff. It's extremely common in diabetes and kidney disease, and it dramatically increases the risk of heart attack and stroke. Currently, no approved drug can reverse it once it starts — doctors can only try to slow its progression through managing risk factors like blood pressure and blood sugar.

How can a growth hormone peptide help blood vessels without raising growth hormone?

The researchers found that the GHRH agonist MR409 works through a separate pathway — it activates the anti-aging protein Klotho and reduces oxidative stress in blood vessels. These effects suppress the bone-forming genes that drive calcium deposition. This mechanism is independent of growth hormone release, which is important because elevated growth hormone can have its own negative effects.

Read the original research

Growth hormone-releasing hormone agonist attenuates vascular calcification in diabetic db/db mice.

Frontiers in cardiovascular medicine, 10, 1102525

View on PubMed ↗Publisher’s paper ↗

Citation

Ren, Hao-Lin; Cai, Ruiping; Xue, Ruize; Zhang, Yaoxia; Xu, Qian; Zhang, Xianyang; Cai, RenZhi; Sha, Wei; Schally, Andrew V; Zhou, Ming-Sheng. (2023). Growth hormone-releasing hormone agonist attenuates vascular calcification in diabetic db/db mice.. Frontiers in cardiovascular medicine, 10, 1102525. https://doi.org/10.3389/fcvm.2023.1102525